BNP PARIBAS ASSET MANAGEMENT Holding S.A. Raises Stock Position in Moderna, Inc. (NASDAQ:MRNA)

BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 51.8% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 85,473 shares of the company’s stock after acquiring an additional 29,177 shares during the quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A.’s holdings in Moderna were worth $5,712,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. EP Wealth Advisors LLC bought a new stake in shares of Moderna in the 1st quarter valued at approximately $254,000. Lazard Asset Management LLC increased its position in Moderna by 81.4% during the 1st quarter. Lazard Asset Management LLC now owns 10,171 shares of the company’s stock valued at $1,082,000 after purchasing an additional 4,563 shares during the period. B. Riley Wealth Advisors Inc. raised its holdings in shares of Moderna by 18.6% in the 1st quarter. B. Riley Wealth Advisors Inc. now owns 9,871 shares of the company’s stock valued at $1,020,000 after purchasing an additional 1,549 shares in the last quarter. California State Teachers Retirement System lifted its position in shares of Moderna by 0.6% in the 1st quarter. California State Teachers Retirement System now owns 521,204 shares of the company’s stock worth $55,539,000 after purchasing an additional 2,980 shares during the period. Finally, Consultiva Wealth Management CORP. bought a new position in shares of Moderna during the first quarter valued at approximately $51,000. Institutional investors own 75.33% of the company’s stock.

Moderna Price Performance

Shares of NASDAQ MRNA opened at $41.11 on Monday. Moderna, Inc. has a 52 week low of $35.80 and a 52 week high of $170.47. The company has a quick ratio of 4.20, a current ratio of 4.39 and a debt-to-equity ratio of 0.05. The firm has a market cap of $15.82 billion, a P/E ratio of -7.06 and a beta of 1.69. The business’s 50 day moving average price is $54.96 and its 200 day moving average price is $93.90.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.89) by $1.92. The firm had revenue of $1.90 billion for the quarter, compared to analyst estimates of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The business’s quarterly revenue was up 3.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.39) earnings per share. On average, sell-side analysts expect that Moderna, Inc. will post -9.44 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on MRNA. Oppenheimer lowered Moderna from an “outperform” rating to a “market perform” rating in a report on Friday, September 13th. The Goldman Sachs Group dropped their price objective on Moderna from $178.00 to $139.00 and set a “buy” rating on the stock in a research report on Monday, September 16th. Leerink Partners cut their target price on Moderna from $60.00 to $48.00 and set an “underperform” rating on the stock in a research note on Tuesday, September 17th. TD Cowen lowered their price target on shares of Moderna from $70.00 to $60.00 and set a “hold” rating on the stock in a report on Friday, September 13th. Finally, Sanford C. Bernstein began coverage on shares of Moderna in a research note on Thursday, October 17th. They set a “market perform” rating and a $55.00 price objective for the company. Three analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $84.00.

Insiders Place Their Bets

In other news, CFO James M. Mock sold 715 shares of the company’s stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $60.12, for a total value of $42,985.80. Following the sale, the chief financial officer now owns 9,505 shares in the company, valued at $571,440.60. This represents a 7.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In the last three months, insiders have sold 2,930 shares of company stock valued at $217,170. Company insiders own 15.70% of the company’s stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.